CARDIFF, Wales--(BUSINESS WIRE)--Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many in partnership with pharmaceutical companies.

。这项投资将促进该公司的发展，包括任命加强团队和继续开发其抗体设计方案，其中许多方案是与制药公司合作的。

The latest investment round was led by i&i Biotech Fund I (i&i Bio) and Kadmos Capital, with additional investment from existing investors InnoSpark Ventures, UKI2S (managed by Future Planet Capital), Tensor Ventures, and AngelHub. This brings the total equity financing raised to £7.2M ($10.1M)..

最近一轮投资由i＆i Biotech Fund i（i＆i Bio）和Kadmos Capital牵头，现有投资者InnoSpark Ventures、UKI2S（由Future Planet Capital管理）、Tensor Ventures和AngelHub进行了额外投资。这使得股权融资总额达到720万英镑（1010万美元）。

The funding will be used to expand the Company’s laboratory and machine learning teams, bolstering the development of its internal assets against G-protein-coupled receptors (GPCRs) and ion channels towards the clinic, as well as facilitating ongoing collaborations with pharma and biotech companies.

这笔资金将用于扩大该公司的实验室和机器学习团队，支持其针对G蛋白偶联受体（GPCR）和离子通道的内部资产的开发，以及促进与制药和生物技术公司的持续合作。

The funding will also be used to improve the predictive accuracy of the design platform, focusing on curating training data. Lastly, Antiverse has opened new facilities in Boston, MA, and Prague, Czech Republic, demonstrating its expansion..

资金还将用于提高设计平台的预测准确性，重点是管理培训数据。最后，Antiverse在马萨诸塞州波士顿和捷克共和国布拉格开设了新设施，展示了其扩张。

Antiverse uses a machine-learning-centred approach to design antibodies for challenging targets, helping to bring needed therapies to patients. The current version of the platform uses ‘target-specific libraries’. These libraries are designed by using structural and sequence data to generate a library with high confidence against the target.

Antiverse使用以机器学习为中心的方法来设计具有挑战性的目标的抗体，有助于为患者带来所需的治疗。该平台的当前版本使用“特定于目标的库”。这些库是通过使用结构和序列数据来设计的，以生成针对目标的高可信度库。

This enhances the predictive accuracy compared to traditional antibody libraries, enabling Antiverse to design antibodies for many challenging targets, including GPCRs and ion channels. The platform accelerates the antibody discovery process to 6 months..

与传统抗体库相比，这提高了预测准确性，使Antiverse能够为许多具有挑战性的靶标（包括GPCR和离子通道）设计抗体。该平台将抗体发现过程加速至6个月。

Murat Tunaboylu, Co-Founder and CEO of Antiverse said: “A third of all FDA-approved drugs target GPCRs, yet, despite decades of research and billions of funding, only a few GPCR-targeting antibodies exist. Thanks to the support of our investors, we are one step closer to making GPCRs and other challenging targets druggable, bringing needed therapies to patients across the globe.”.

Antiverse联合创始人兼首席执行官穆拉特·图纳博伊卢（MuratTunaboylu）表示：“FDA批准的所有药物中，有三分之一针对GPCR，然而，尽管进行了数十年的研究和数十亿资金，但只有少数针对GPCR的抗体存在。多亏了我们投资者的支持，我们离使GPCR和其他具有挑战性的目标药物化更近了一步，为全球患者带来了所需的治疗。”

Jaromir Zahradka, CEO at i&i Bio, commented: “Antiverse has made significant progress in the field of antibody design. Antiverse's mission to make GPCRs druggable focuses on a key issue and we are pleased to be supporting them.”

i＆i Bio首席执行官Jaromir Zahradka评论道：“Antiverse在抗体设计领域取得了重大进展。Antiverse使GPCR可药用的使命集中在一个关键问题上，我们很高兴支持他们。”

John Gebeily, Operating Partner at Kadmos Capital, added: “Antiverse's AI-driven antibody design platform demonstrates significant potential in advancing the development of novel antibody therapeutics, particularly for complex drug targets. We're excited to support Murat and the team in their effort to significantly accelerate the development of life-saving treatments, and have a transformative impact on the pharmaceutical industry.”.

Kadmos Capital的运营合伙人John Gebeily补充道：“Antiverse的人工智能驱动的抗体设计平台在推进新型抗体疗法的开发方面显示出巨大的潜力，特别是对于复杂的药物靶标。我们很高兴支持Murat及其团队努力显着加速救生治疗的开发，并对制药行业产生变革性影响。”